🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Consumer Staples Sector SEC Filings — April 08, 2026

Across 50 filings in the USA S&P 500 Consumer Staples intelligence stream (though spanning broader sectors), proxy statements dominate (17+ filings) signaling intense AGM season in May 2026, with boards pushing declassification, auditor ratifications, and say-on-pay votes amid stable governance. Earnings reports show mixed period-over-period trends: 9/18 quantifiable filings reported revenue growth averaging +20% YoY (e.g., Delta +13%, RPM +8.9%, ImmuCell +28.4%), but 4 saw sharp declines (Constellation -10%, Mobiquity -95%, Safe & Green dilution risks); margins improved in 4/10 (Richardson +110 bps to 31.9%, RPM EBIT +48.8%) but compressed elsewhere (Constellation Beer -170 bps). Capital allocation leans shareholder-friendly with $255M returns at RPM (+5.2% YoY), $1.6B at Constellation, and steady dividends (Ellington $0.08/share, Constellation +1% to $1.03); M&A active in tuck-ins (PMGC 4 deals, RPM Kalzip) and divestitures (Atkore HDPE sale). Forward guidance mixed: reaffirmations (RPM mid-single digits), raises (Delta low-teens Q2 revenue), cuts/withdrawals (Constellation FY28 outlook gone). Sentiment mixed/neutral overall (28/50), with portfolio-level theme of resilient sales growth masking consumer softness (RPM Consumer -2.4% organic). Implications: Favor dividend payers and M&A consolidators; watch May catalysts for guidance updates amid economic uncertainty.

16 high priority 34 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — April 08, 2026

Across 50 filings in the USA S&P 500 Industrials stream, key themes include robust revenue growth in transportation and chemicals (e.g., Delta +9.4% YoY, RPM +8.9% YoY, Venture Global +177% YoY) offset by margin pressures and one-off losses (Delta op margin - to 3.2%, Regeneron $102M IPR&D charge). M&A activity surges with deals like Corebridge-Equitable all-stock merger (close YE2026), Day One tender at $21.50/share (antitrust cleared), and Catalyst Bancorp $41.1M acquisition (180% EPS accretive). Proxy season dominates with 15+ DEF/DEFA14A filings for May 2026 meetings, signaling governance focus amid neutral sentiment. 18 13F-HR filings reveal institutional stability in industrials/transports (e.g., CSX, H2O America) and ETFs, with no major shifts. Capital returns strong at RPM ($255M +5.2% YoY). Forward guidance mixed: RPM mid-single-digit Q4 sales, Delta low-teens June rev. Sector implications point to resilient demand but cost headwinds, with catalysts in Q2 earnings and meetings.

15 high priority 35 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — April 08, 2026

Across 10 SEC filings from the S&P 500 Energy stream (with some adjacent sectors), overarching themes include robust shareholder engagement via proxy materials and AGMs, proactive capital returns through special distributions and dividend approvals, and neutral-to-positive sentiment amid earnings preparations and credit access, contrasted by risk disclosures in LNG shipping. No explicit period-over-period financial declines are noted, but XOM highlights leading 29% five-year total annualized shareholder returns among IOCs driven by Permian, Guyana, and LNG growth, signaling sector strength in upstream advantaged assets. Critical developments feature Vistance's $10/share special cash distribution (funded by asset sale, avoiding leverage amid volatility) and CommScope's $300M revolver, indicating liquidity bolstering; SLB's unanimous AGM approvals reflect governance confidence. Portfolio-level patterns show 4/10 filings positive (e.g., distributions, performance boasts), 1 negative (LNG risks), and 5 neutral (proxies, exhibits), with no YoY/QoQ deteriorations but forward catalysts like XOM's May 27 meeting and Vistance payment April 27. Market implications favor near-term yield plays and monitoring Middle East impacts on XOM operations.

4 high priority 6 medium 10 total filings
· daily

US Material Events SEC 8-K Filings — April 08, 2026

Across 43 filings from April 8, 2026, dominant themes include widespread executive transitions (17 instances, particularly CFO appointments/resignations in 9 cases), signaling strategic shifts amid sector pressures; robust M&A and financing activity (10 deals/facilities, including bank acquisitions doubling assets and $1.5B+ credit lines); and liquidity enhancements via credit extensions and equity raises without noted performance declines. No broad period-over-period revenue/margin declines reported, with accretive M&A (e.g., 180% EPS accretion) and positive forward guidance in biotech/energy standing out vs. neutral executive churn. Mixed sentiment in leadership losses (e.g., CEO passing) contrasts bullish capital raises and AI expansions, implying portfolio-level opportunities in banking consolidation and infrastructure plays. Critical implications: monitor transition risks in financials/tech, capitalize on accretive deals pre-Q3 closes. Aggregate capital allocation favors reinvestment (RSUs/bonuses) over buybacks/dividends, with no insider selling patterns detected.

43 high priority 43 total filings
· daily

Dow Jones 30 Stocks SEC Filings — April 08, 2026

Across 50 SEC filings from Dow Jones 30-related entities on April 8, 2026, dominant themes include a proxy season surge with 15+ DEF 14A/DEFA14A filings for May 2026 AGMs, robust M&A activity (e.g., Clearwater sale process, Kenvue-Kimberly-Clark merger, CECO-Thermon), and mixed financial trends: explosive energy growth (Venture Global revenue +177% YoY to $13.8B) offset by consumer/healthcare softness (Kenvue sales -2.1% YoY, Avalyn losses +71% YoY to $85.2M). Institutional 13F-HR filings (12 total) reveal persistent heavy allocations to tech giants (Apple, Amazon, NVIDIA across 8+ filers) and ETFs, signaling broad market conviction in megacaps amid volatility. Capital allocation leans shareholder-friendly with buybacks (Voya $300M in Q1/Q2 2026, Intel $14.2B JV repurchase), while operational wins like Brookdale occupancy +250bps YoY to 82.0% highlight recovery plays. Portfolio-level trends show margin resilience (Kenvue op margin +410bps to 16.0%) despite top-line pressures, with forward catalysts clustered in H2 2026 mergers and May AGMs. Overall, blue-chip stability persists, but M&A and energy outliers offer alpha amid Nasdaq compliance risks in small-caps.

18 high priority 32 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — April 08, 2026

Across 50 SEC filings for April 8, 2026, dominant themes include robust capital allocation via dividends and buybacks in REITs (Kimco +4% YoY dividends, 6.1M shares repurchased), surging revenues in niche growth sectors like LNG (Venture Global +177% YoY to $13.8B) and refurbished electronics (ATRenew +28.9% YoY to profitability), contrasted by biotech headwinds (Nurix revenue -66% YoY, net loss widened to $87M). M&A momentum accelerates with FTC clearances (Day One tender at $21.50/share, CECO-Thermon HSR terminated), merger filings (Corebridge-Equitable all-stock deal targeting YE2026 close), and crypto mining approvals (Coeptis-Z Squared). Period-over-period trends show 4/7 key revenue reporters with >20% YoY growth (avg +79%), but cash burn in biotechs (Nurix cash -71% QoQ, SmartKem -95% YoY) and mixed cash flows (ATRenew operating cash -165% YoY). 13F-HR filings (14 total) reveal institutional tilt to tech megacaps (Apple, Amazon, NVIDIA ubiquitous) and ETFs, signaling defensive positioning. Forward catalysts cluster in Q2 2026 mergers and May proxy votes, with 2026-2027 pipelines in AI/autonomous (PlusAI $1B ARR target) and nuclear (Nano Nuclear UF6 facility). Overall, actionable alpha in energy/REITs amid biotech caution, with portfolio-level margin expansion in winners (Venture Global op income +192% YoY).

20 high priority 30 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 08, 2026

Across 50 filings in the S&P 500 Consumer Discretionary stream (despite diverse inclusions like SPACs, financials, and energy), key themes include mixed financial performance with revenue growth in retail (e.g., PriceSmart +9.8% YoY six months, Ingles +6.6% Q1 FY2026) offset by operational declines (Harbor Diversified RPMs -20.1% YoY) and widening losses (SmartKem net loss despite +750% revenue, Franklin Covey Q1 loss widened to $2.0M). Proxy battles and annual meetings dominate (15+ DEF/DEFA14A filings), signaling governance focus amid May 2026 catalysts, while M&A activity shines (Fifth Era SPAC merger with Miotal, Corebridge-Equitable all-stock deal targeting YE2026 close). Capital allocation leans shareholder-friendly (Voya $300M buybacks Q1-Q2 2026, Rexford $250M repurchases), but cash burn risks persist (SmartKem cash -95% to $374k). Institutional 13F snapshots (10+ filings) show heavy ETF/tech tilts with no major shifts. Forward catalysts cluster in May 2026 AGMs/earnings, with positive sentiment in 20% of filings driving outperformance potential in retail/restaurants vs sector drags in airlines/transport.

26 high priority 24 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — April 08, 2026

Across 50 filings in the USA S&P 500 Healthcare stream, healthcare-specific insights dominate with positive biotech momentum from Ensysce's $20M funding commitment, TuHURA's Kineta acquisition and $12.6M raise, Precision BioSciences' 115% scorecard attainment and $75M cash extension to 2028, Castle Biosciences' $344M 2025 revenue exceeding guidance with 37% YoY test volume growth, and Merck's $70B pipeline opportunity by mid-2030s (up $20B YoY) amid multiple FDA approvals. Contrasting this, Regeneron flagged a $102M Q1 2026 IPR&D charge impacting EPS by -$0.81, signaling acquisition-related costs. Proxy statements proliferate for May 2026 AGMs (Merck May 26, Castle May 28), highlighting strong pay-vs-performance and board elections. Institutional 13Fs (e.g., Civilization Ventures' $52M Natera, $90M BillionToOne; Lynch's $21M J&J) indicate sustained healthcare allocations amid diversified portfolios. Non-healthcare filings (financials, advisors) show buyback trends (Voya $300M total, Chewy $500M increase) and M&A (Corebridge-Equitable), but healthcare trends point to growth in diagnostics/biotech offset by one-off charges, with no broad margin compression or insider selling patterns.

18 high priority 32 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — April 08, 2026

Across 50 DEF 14A proxy statements filed around April 8, 2026, for May 2026 annual meetings, overarching themes include routine approvals for director elections (avg 8-12 nominees, 80%+ independent), advisory say-on-pay votes (with pay-vs-performance disclosures for 2021-2025 across most), and auditor ratifications, amid strong 2025 financials in energy (e.g., Venture Global +177% YoY revenue) and REITs (Kimco 96.4% occupancy), contrasted by consumer softness (Kenvue -2.1% sales YoY). Portfolio-level trends show 12/50 companies reporting revenue growth >10% YoY (avg +45% in energy), margin expansions in 8/50 (e.g., Kenvue op margin +410 bps), and robust capital allocation like dividends +4% YoY (Kimco) and buybacks (Rexford $250M). Positive sentiment dominates energy/REITs (9/10 high materiality), mixed/neutral in biotech/healthcare due to comp cuts (Precision Bio CEO -49%) despite goal attainments. Critical developments: Kenvue-Kimberly-Clark merger close H2 2026, ProPetro PROPWRSM scaling to 550 MW, and board refreshes signaling governance upgrades. Market implications favor energy/REIT overweight amid growth, caution on consumer/biotech volatility pre-meetings.

50 high priority 50 total filings
· daily

US IPO Pipeline SEC S-1 Filings — April 08, 2026

The IPO Pipeline stream reveals a surge in activity with four S-1 filings on April 7-8, 2026, spanning infrastructure (IRRX), biotech (Avalyn Pharma), crypto ETF (Canary PEPE), and healthcare services (Avalon GloboCare), alongside CECO Environmental's S-4 for its Thermon merger, highlighting M&A-driven share issuance. Key period-over-period trends include Avalyn Pharma's net losses widening 71% YoY to $85.2M in 2025 (from $49.7M in 2024), R&D expenses up 67% to $76.6M, and G&A up 29% to $14.7M, with accumulated deficit ballooning to $265.4M; no comparable financial trends in other filings but Avalon's board turnover signals governance shifts. Mixed/neutral sentiments dominate (4/5 filings), with high materiality (avg 8.6/10), underscoring speculative pre-IPO positioning amid strong cash runway ($138.4M at Avalyn). Portfolio-level patterns show biotech burn rates accelerating while infrastructure and crypto products eye Nasdaq listings, with CECO's early HSR clearance (April 2, 2026) as a merger catalyst. Market implications include near-term IPO pops, merger arbitrage potential, and volatility from meme assets, favoring tactical plays in high-conviction names.

5 high priority 5 total filings
· daily

Global High-Priority Regulatory Events — April 08, 2026

Across 50 filings on April 8, 2026, dominant themes include a surge in M&A/SPAC activity (e.g., Fifth Era-Miotal, Securitize-Currenc tokenization, Corebridge-Equitable merger), proxy statements signaling 2026 annual meeting season with strong 2025 recaps in select firms (Qnity 10-12% growth, Kimco 96.4% occupancy), and Indian market filings highlighting insolvencies/resolutions (CIAN Agro positive, SKIL CIRP ongoing) alongside RBI monetary policy holding repo at 5.25% with GDP growth forecast moderation to 6.9% FY2027. Period-over-period trends show revenue growth in 12/20 reporting companies averaging +24% YoY (e.g., ATRenew +28.9%, Jabil +23%), but margin compression and cash burns in biotech (Nurix -66% revenue, SmartKem cash -95%), mixed cannabis (Grown Rogue +22% revenue but segment declines). Capital allocation leans positive with buybacks (Aurobindo ₹800 Cr, Kimco 6.1M shares), while risks emerge from defaults (Prag Bosimi ₹9.06 Cr dividend) and regulatory fines. Portfolio-level patterns indicate bullish industrials/REITs/M&A vs bearish biotech/small caps; implications favor event-driven strategies around May meetings and H1 merger closes amid neutral RBI stance supporting credit growth +14.3% YoY.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — April 08, 2026

Across 26 filings in the Financial Results & Earnings stream, results are predominantly mixed (17/26), with revenue growth in 12 companies averaging +40% YoY (outliers: Applied Digital +139%, Pure Cycle +47%) offset by sharp declines in 10 others (avg -40% YoY, e.g., Nurix -66%, Aehr -44%). Margin compression is widespread (8/26 companies, avg -150 bps), driven by rising opex/R&D, while net losses widened in 14 firms amid impairments (e.g., Beasley $225M FCC licenses) and cash burn (15/26 cash declines, avg -50%). Positive net income in 6 companies (e.g., Grown Rogue turnaround to $3.2M profit, Jabil +91% YoY) contrasts small-cap struggles, with biotech/pharma and media hit hardest. Capital allocation favors buybacks/dividends in performers (e.g., Pure Cycle repurchases, PriceSmart dividends up), but equity issuances dilute in cash-strapped firms (17/26). Portfolio implication: Rotate into revenue growers like Jabil/Applied Digital; avoid cash-deficient microcaps. Forward risks from low cash (SmartKem $374k) and SPAC deadlines signal near-term catalysts.

26 high priority 26 total filings
· daily

US SEC Trading Suspension Halt Orders — April 08, 2026

The USA Trading Suspensions stream features one key filing from SPAR Group, Inc. (SGRP), highlighting acute Nasdaq compliance failure with stockholders’ equity at just $622,000 as of December 31, 2025, versus the required $2.5 million minimum, alongside failures in alternative criteria of $35 million market value or $500,000 net income. No period-over-period comparisons available in the filing, but the equity deficiency signals ongoing financial deterioration into YE 2025 from prior 10-K data. This represents a 10/10 materiality event with negative sentiment, posing immediate delisting risk on Nasdaq Capital Market. Portfolio-level trends are limited to this single instance in a very quiet session, but it underscores small-cap vulnerability to regulatory halts. Market implications include potential trading suspension, heightened volatility, and forced liquidation pressures for holders. No bullish offsets from insider activity, capital allocation, or forward guidance noted.

1 high priority 1 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 08, 2026

The 22 filings in the USA Corporate Distress & Bankruptcy stream reveal a landscape dominated by liquidity-seeking maneuvers, with 6 companies pursuing dilutive equity raises (ATM offerings, convertible preferred stock) totaling over $100M in capacity, signaling cash burn pressures in microcaps despite no outright bankruptcies. Distress signals are concentrated: SPAR Group's stockholders' equity at $622K vs. $2.5M Nasdaq minimum (Dec 31, 2025), KBS REIT III's explicit going concern doubt tied to $160.4M loan maturities by Dec 2026, Bitcoin Depot's $3.665M cyber theft loss, and Mosaic's $350-400M Q1 2026 Brazil impairment. Counterbalancing positives include M&A-driven growth (Catalyst Bancorp doubling assets to $627M, 180% EPS accretive; Odyssey Marine's $1B pro forma merger with $175M cash at close) and debt extensions (Dominion to 2031, Dover 5-year revolver). Sentiment skews positive/neutral (18/22), but materiality clusters around 8-10/10 for key risks/opportunities. No broad YoY/QoQ declines reported across filings, but asset sales (KBS $48.1M net) and idlings highlight operational retrenchment. Portfolio implication: Avoid pure distress plays like SPAR/KBS; favor consolidators like Catalyst/Odyssey for turnaround alpha.

22 high priority 22 total filings
· daily

US Executive Officer Management Changes SEC — April 08, 2026

Across 23 SEC 8-K filings on USA executive and director changes from April 8, 2026, a high volume of leadership transitions is evident, with 12 new appointments/promotions (e.g., CFOs at FactSet, Universal Logistics, Forward Industries) and 8 departures/resignations (e.g., CFO at Scorpius, CEO at SoCalGas), signaling sector-wide refreshes amid strategic shifts. Finance and banking dominate (9/23 filings, including MVB, Popular, FinWise), showing proactive succession planning with positive sentiment in 40% of cases, while tech/AI firms like Mawson Infrastructure highlight activist-driven overhauls. No explicit YoY/QoQ financial deteriorations noted, but sudden events like Horizon Kinetics CEO death introduce mixed sentiment and transition risks; equity grants/RSUs in 5 filings (e.g., SpringBig's 12.9M CEO RSUs) indicate retention-focused capital allocation. Portfolio-level pattern: Smooth transitions with experienced hires (avg 20+ years exp in 7 cases) suggest stability, but interim roles (e.g., SoCalGas COO) flag near-term execution risks. Market implications include potential volatility around effective dates (cluster Apr-May 2026) and opportunities in undervalued firms post-turnover.

23 high priority 23 total filings
· daily

US Corporate Board Director Changes SEC Filings — April 08, 2026

Across 23 SEC 8-K filings on USA Board Room Changes dated April 8, 2026, there is elevated C-suite turnover, with 8 CFO transitions (resignations at Scorpius, Universal; appointments at FactSet, Spectral AI, Forward Industries, Catalyst Crew, Universal successor), 7 CEO-related shifts (new agreements at SpringBig/Parks America, death at Horizon Kinetics with co-CEOs, resignations at SoCalGas, new CEOs at Mawson/Navient/FinWise), and multiple director resignations (Byrna, OFA Group, Patriot National, USCB). Sentiment skews neutral (12/23) with positive tones on experienced hires and smooth successions (8 positive), mixed only at Horizon due to sudden loss of founder-CEO. No explicit YoY/QoQ financial trends or insider buys/sells reported, but equity-heavy comp packages (e.g., SpringBig CEO 12.9M RSUs, Spectral 150K options) and Change-in-Control protections signal retention amid M&A risks/opportunities. Financial sector dominates (9/23 filings: MVB, FactSet, Horizon, Universal, Patriot, Popular, Navient, FinWise, USCB) with planned transitions enhancing stability, while sudden events (Horizon death, SoCalGas CEO exit) raise interim leadership risks. Portfolio implication: Monitor finance/banking for execution continuity; leadership upgrades in tech/biotech (FactSet, Spectral, Mawson) offer relative outperformance potential vs. laggards with voids.

23 high priority 23 total filings
· daily

US Merger & Acquisition SEC Filings — April 08, 2026

The 7 filings underscore a vibrant SPAC and M&A landscape on April 8, 2026, dominated by routine post-IPO unit separation announcements in 4 blank check companies (Abony, Averin, Metals II, and contextually similar), signaling increased liquidity and readiness for business combinations in defense tech, health/tech, and metals sectors. Key outliers include Air Lease Corp's takeover completion by Sumisho (rename and capital restructure), DMAA's positive $1B non-binding LOI with Power Analytics Global Corp for de-SPAC (min $25-50M cash, potential PIPE), and Eureka Acquisition Corp's dual negative developments: a $150k working capital promissory note and delisting notice effective April 6. Sentiment is neutral across 5/7 filings, positive for DMAA (high materiality 9/10), and negative for Eureka delisting (9/10 materiality), with no explicit period-over-period financial trends but clear forward-looking catalysts like unit separations April 10-14 and LOI progression. No insider trading or capital allocation shifts beyond Air Lease's stock reclassification and preferred series designations noted; transaction details highlight undervalued SPAC targets ($750M-$1.5B for Abony) vs DMAA's $1B valuation. Portfolio-level pattern: SPAC maturation post-IPO accelerates M&A potential, but delisting risks underscore selection discipline. Implications: Bullish for de-SPAC hunters in targeted sectors, bearish caution on distressed SPACs like Eureka.

7 high priority 7 total filings
· monthly

US Pre-Market SEC Filings Roundup — April 08, 2026

Overnight SEC filings reveal a mix of robust operational performances in energy/REITs (e.g., Venture Global +177% YoY revenue, Kimco 96.4% occupancy) contrasted by biotech cash burn and revenue declines (Nurix -66% YoY revenue, cash -71% QoQ), with 50 filings dominated by neutral 13F-HR snapshots showing heavy ETF/tech allocations amid institutional positioning. Aggregate period trends show 4/7 key financial reporters with YoY revenue growth averaging +50% (ATRenew +28.9%, Grown Rogue +22%), but margins mixed due to cost inflation (Nurix op ex +21%, SmartKem op loss widened); capital returns strong via dividends/buybacks (Kimco +4% div, 6.1M shares repurchased). M&A catalysts accelerate with FTC clearances (Day One tender, CECO-Thermon HSR done), IPO expansions (Legence +2.7M shares), and SPAC updates (PlusAI/Churchill). Positive sentiment in 6/50 filings highlights shareholder returns and growth, while mixed/negative in biotechs flag liquidity risks. Portfolio implications favor energy/REIT longs, biotech shorts, with May proxy season as key volatility driver.

19 high priority 31 medium 50 total filings
· daily

Biotech Small-Cap Approvals — April 07, 2026

The FDA recorded 2 'Other' approvals in the Biotech Small-Cap stream from April 07, 2026 to April 07, 2026 (0 NMEs, 0 biosimilars, 0 label expansions), both neutral signals (5/10 strength and materiality). DEXCEL and APOTEX each gained FDA approval for biosimilar NINTEDANIB ESYLATE on 2026-04-02, enabling small-cap entrants into the nintedanib market originally dominated by Boehringer Ingelheim's Ofev. No dominant therapeutic area theme emerges, as details like indication and market sizing remain NOT_DISCLOSED. The highest-conviction signal is the NINTEDANIB ESYLATE biosimilar approvals for DEXCEL and APOTEX, offering neutral commercial entry potential with limited disclosed upside. Key risk/watch item is competitive erosion to Boehringer Ingelheim's originator franchise (30-60% revenue risk over 2-3 years).

2 total filings
· daily

Big Pharma Approvals — April 07, 2026

The FDA approval period from April 07, 2026 to April 07, 2026 featured 0 NMEs, 0 biosimilars, 0 label expansions, and 1 Other approval in the Big Pharma stream. Regeneron Pharmaceuticals secured a bullish label expansion for Aflibercept (Eylea HD), providing a moderate commercial signal with strength and materiality rated 5/10. No dominant therapeutic area theme is evident from this single event. The highest-conviction signal is Regeneron’s Aflibercept label expansion, which reinforces sponsor execution in an established franchise. Key risk/watch item: lack of disclosed peak sales, exclusivity, pricing, or market position data warrants monitoring for post-approval commercial uptake.

1 total filings